Lineage Cell Therapeutics’ (LCTX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) in a research report sent to investors on Monday,Benzinga reports. The firm currently has a $2.00 target price on the stock.

A number of other brokerages also recently commented on LCTX. HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of Lineage Cell Therapeutics in a research report on Monday. B. Riley cut their price objective on Lineage Cell Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, March 14th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Lineage Cell Therapeutics has a consensus rating of “Buy” and an average target price of $4.20.

Lineage Cell Therapeutics Price Performance

LCTX opened at $1.07 on Monday. The company has a market capitalization of $244.35 million, a price-to-earnings ratio of -13.38 and a beta of 1.52. Lineage Cell Therapeutics has a 1-year low of $0.37 and a 1-year high of $1.15. The business has a 50 day moving average price of $0.62 and a two-hundred day moving average price of $0.62.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Rhumbline Advisers grew its stake in Lineage Cell Therapeutics by 9.9% during the 1st quarter. Rhumbline Advisers now owns 201,447 shares of the company’s stock valued at $91,000 after acquiring an additional 18,092 shares in the last quarter. HighTower Advisors LLC lifted its holdings in shares of Lineage Cell Therapeutics by 49.5% during the 4th quarter. HighTower Advisors LLC now owns 57,706 shares of the company’s stock valued at $29,000 after buying an additional 19,100 shares during the last quarter. Barclays PLC lifted its holdings in shares of Lineage Cell Therapeutics by 10.8% during the 4th quarter. Barclays PLC now owns 234,069 shares of the company’s stock valued at $118,000 after buying an additional 22,769 shares during the last quarter. Fort Sheridan Advisors LLC lifted its holdings in shares of Lineage Cell Therapeutics by 71.5% during the 4th quarter. Fort Sheridan Advisors LLC now owns 55,177 shares of the company’s stock valued at $28,000 after buying an additional 23,000 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in shares of Lineage Cell Therapeutics by 33.0% during the 4th quarter. Wells Fargo & Company MN now owns 94,894 shares of the company’s stock valued at $48,000 after buying an additional 23,527 shares during the last quarter. Hedge funds and other institutional investors own 62.47% of the company’s stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.